-
4m 27sPart 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
7m 20sPart 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
3m 38sPart 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
-
47m 54sPart 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
36m 33sPart 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
11m 8sPart 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
19m 8sPart 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 11sPart 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
14m 10sPart 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 4sPart 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
12m 24sPart 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
12m 36sPart 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
14m 3sPart 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
14m 30sPart 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
27m 8s
-
4m 15sPart 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
3m 52sPart 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
5m 10s
-
7m 42sPart 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
7m 12s
-
6m 54sPart 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
10m 5sPart 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
7m 43s
-
6m 35sPart 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
5m 6sPart 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
3m 53sPart 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
4m 31sPart 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
6m 37sPart 4 | Session 13 Pooled MACE Data for Obicetrapib
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.
Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.
Findings showed that semaglutide produced consistent improvements in functional outcomes in patients with symptomatic PAD and type 2 diabetes, irrespective of sex.
Recorded on-site at ESC Congress 2025, Madrid.
Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.
Comments